Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Spinal muscular atrophy type 1 (SMA1) is a progressive, monogenic motor neuron disease with an onset during infancy that results in failure to achieve motor milestones and in death or the need for mechanical ventilation by 2 years of age. We studied functional replacement of the mutated gene encoding survival motor neuron 1 (SMN1) in this disease. METHODS: vg per kilogram). The primary outcome was safety. The secondary outcome was the time until death or the need for permanent ventilatory assistance. In exploratory analyses, we compared scores on the CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scale of motor function (ranging from 0 to 64, with higher scores indicating better function) in the two cohorts and motor milestones in the high-dose cohort with scores in studies of the natural history of the disease (historical cohorts). RESULTS: As of the data cutoff on August 7, 2017, all 15 patients were alive and event-free at 20 months of age, as compared with a rate of survival of 8% in a historical cohort. In the high-dose cohort, a rapid increase from baseline in the score on the CHOP INTEND scale followed gene delivery, with an increase of 9.8 points at 1 month and 15.4 points at 3 months, as compared with a decline in this score in a historical cohort. Of the 12 patients who had received the high dose, 11 sat unassisted, 9 rolled over, 11 fed orally and could speak, and 2 walked independently. Elevated serum aminotransferase levels occurred in 4 patients and were attenuated by prednisolone. CONCLUSIONS: In patients with SMA1, a single intravenous infusion of adeno-associated viral vector containing DNA coding for SMN resulted in longer survival, superior achievement of motor milestones, and better motor function than in historical cohorts. Further studies are necessary to confirm the safety and efficacy of this gene therapy. (Funded by AveXis and others; ClinicalTrials.gov number, NCT02122952 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, the FDA has approved AAV for gene replacement therapy in spinal muscular atrophy and congenital blindness, and clinical trials are in progress 58 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [58]
In the citing paper
“preclinical and clinical studies have demonstrated dose-dependent inflammation, which can reduce efficacy and lead to dose-limiting toxicity (2–8)”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [4]
In the citing paper
“Although neuroimaging is typically more expensive than EEG and studies are limited by issues of replication, sometimes that is related to head motion that occurred during the scan which can erode signal 61”
From Autism spectrum disorder (2020) · cites this paper as [61]
In the citing paper
“Especially considering the ability of the recombinant AAV genome to persist as an episome in post-mitotic cells, such as neurons, which ensures long-term expression even after a single administration [130-132].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [132]
In the citing paper
“With AAV9’s inherent ability to target motor neurons, AAV9-based Zolgensma® for the treatment of SMA has been established as the first FDA-approved drug for systemic gene therapy in CNS diseases [171].”
From Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside (2024) · cites this paper as [171]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
Self-citationRetractedDeaths: preliminary data for 2003.
Hoyert, D. L., Kung, H.-C., & Smith, B. L. (2005) · PubMed · Cited by 1,649
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Self-citationBayley Scales of Infant and Toddler Development, Third Edition
Bayley, N. (2012) · PsycTESTS Dataset · doi:10.1037/t14978-000 · Cited by 1,175
National Vital Statistics Reports NCHS.pdf
Hoyert, D. (2012) · Medical Entomology and Zoology · Cited by 982
Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305788 · Cited by 961 · cited 4×
“Viral upper respiratory tract infection 0 0 3 3 (25) 3 3 (20)”
InfluentialAntisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 664
Sugarman, E. A., Nagan, N., Zhu, H., Akmaev, V. R., Zhou, Z., Rohlfs, E. M., Flynn, K., Hendrickson, B. C., Scholl, T., Sirko-Osadsa, D. A., et al. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.134 · Cited by 661
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 547
de Onis, M., Onyango, A. W., Van den Broeck, J., Chumlea, W. C., & Martorell, R. (2004) · Food and Nutrition Bulletin · doi:10.1177/15648265040251s105 · Cited by 529
Research works printed but not linked: 1
- Hoyert DL, 2012, Natl Vital Stat Rep, 61, 1
Cited by
Items 201–300 of 1,005
Towards a better diagnosis and treatment of Rett syndrome: a model synaptic disorder
Banerjee, A., Miller, M. T., Li, K., Sur, M., & Kaufmann, W. E. (2019) · Brain · doi:10.1093/brain/awy323 · Cited by 107
“improved survival and motor function) single dose intravenous adeno-associated virus serotype 9 delivery of complementary DNA (encoding the SMN protein) in spinal muscular atrophy type 1 (Mendell et al., 2017).”
BackgroundGene therapy for neurological disorders: challenges and recent advancements
Peña, S., Iyengar, R., Eshraghi, R. S., Bencie, N., Mittal, J., Aljohani, A., Mittal, R., & Eshraghi, A. A. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1630415 · Cited by 122
Lofts, A., Abu-Hijleh, F. A., Rigg, N., Mishra, R. K., & Hoare, T. R. (2022) · CNS Drugs · doi:10.1007/s40263-022-00930-4 · Cited by 133
“For instance, a single IV administration of an adeno-associated viral (AAV) vector coding for the mutated survival motor neuron 1 gene (which results in spinal muscular atrophy type 1) resulted in prolonged survival and better motor function than the control group [164].”
BackgroundCurrent Status of and Perspectives on the Application of Marmosets in Neurobiology
Okano, H. (2021) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-030520-101844 · Cited by 102
Exposure to wild-type AAV drives distinct capsid immunity profiles in humans
Kuranda, K., Jean-Alphonse, P., Leborgne, C., Hardet, R., Collaud, F., Marmier, S., Costa Verdera, H., Ronzitti, G., Veron, P., & Mingozzi, F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122372 · Cited by 104
Engineering the AAV capsid to evade immune responses
Barnes, C., Scheideler, O., & Schaffer, D. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.01.002 · Cited by 102
“Fortunately, transient steroidal immunosuppression, until viral capsid proteins are fully degraded, can attenuate this response and is increasingly being adopted in the clinic.[2], [10]”
BackgroundOnasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy
Stevens, D. L., Claborn, M. K., Gildon, B. L., Kessler, T. L., & Walker, C. K. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020914274 · Cited by 112
Carrier strategies boost the application of CRISPR/Cas system in gene therapy
Xu, Z., Wang, Q., Zhong, H., Jiang, Y., Shi, X., Yuan, B., Yu, N., Zhang, S., Yuan, X., Guo, S., et al. (2022) · Exploration · doi:10.1002/exp.20210081 · Cited by 109
Finkel, R. S., Chiriboga, C. A., Vajsar, J., Day, J., Montes, J., Vivo, D. C. D., Bishop, K. M., Foster, R., Liu, Y., Ramirez‐Schrempp, D., et al. (2021) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(21)00100-0 · Cited by 119
Westhaus, A., Cabanes-Creus, M., Rybicki, A., Baltazar, G., Navarro, R. G., Zhu, E., Drouyer, M., Knight, M., Albu, R. F., Ng, B. H., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.264 · Cited by 102
European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy
Kirschner, J., Butoianu, N., Goemans, N., Haberlová, J., Kostera‐Pruszczyk, A., Mercuri, E. M., van der Pol, W. L., Quijano-Roy, S., Sejersen, T., Tizzano, E. F., et al. (2020) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2020.07.001 · Cited by 125
“Onasemnogene abeparvovec (formerly AVXS-101, Zolgensma®) is an adeno-associated viral vector-based gene therapy designed to deliver a functional copy of the SMN1 gene to themotor neurons through a single intravenous infusion [4].”
Dangouloff, T., Botty, C., Beaudart, C., Servais, L., & Hiligsmann, M. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01695-7 · Cited by 115
“Onasemnogene abeparvovec [9, 10], marketed as Zolgensma by Novartis (Basel, Switzerland), was approved by the FDA in May 2019 and the EMA in August 2020.”
BackgroundCapsid-specific removal of circulating antibodies to adeno-associated virus vectors
Bertin, B., Veron, P., Leborgne, C., Deschamps, J.-Y., Moullec, S., Fromes, Y., Collaud, F., Boutin, S., Latournerie, V., van Wittenberghe, L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57893-z · Cited by 100
Malone, D. C., Dean, R., Arjunji, R., Jensen, I., Cyr, P., Miller, B., Maru, B., Sproule, D. M., Feltner, D. E., & Dabbous, O. (2019) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2019.1601484 · Cited by 99
“D to Death Ages 0–30 months: AVXS-101-CL-101 [13,16] 30+ months: Projected overall survival using natural history curve [25] Ages 0–18 months: ENDEAR* [10] 18+ months: Projected overall survival using natural history curve [25] D to E Ages 0–30 months: AVXS-101-CL-101 [13,16] 30+ months: Projected ventilation-free sur…”
BackgroundMethodSelf-citationSplicing repression is a major function of TDP-43 in motor neurons
Donde, A., Sun, M., Ling, J. P., Braunstein, K. E., Pang, B., Wen, X., Cheng, X., Chen, L., & Wong, P. C. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02042-8 · Cited by 99
Molecular stratification of idiopathic nephrotic syndrome
Saleem, M. A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0217-5 · Cited by 111
Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients
Duan, D. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.012 · Cited by 98
“A major breakthrough published in December 2017 has now provided the proof-of-principle for systemic gene therapy in human patients.(1) Mendell et al.”
BackgroundPopulation-based analysis of survival in spinal muscular atrophy
Wijngaarde, C. A., Stam, M., Otto, L. A. M., van Eijk, R. P. A., Cuppen, I., Veldhoen, E. S., van den Berg, L. H., Wadman, R. I., & van der Pol, W. L. (2020) · Neurology · doi:10.1212/wnl.0000000000009248 · Cited by 107
Batista, A. R., King, O. D., Reardon, C. P., Davis, C., Shankaracharya, Philip, V., Gray-Edwards, H., Aronin, N., Lutz, C., Landers, J., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.186 · Cited by 98
“6 The transformative outcomes in children affected with spinal muscular atrophy (SMA) treated by intravascular administration of an AAV9 vector 7 are likely the result of its remarkable tropism for spinal cord motor neurons, which are the primary drivers of the SMA disease phenotype.”
Gene Therapy for ALS—A Perspective
Cappella, M., Ciotti, C., Cohen-Tannoudji, M., & Biferi, M. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184388 · Cited by 98
Muscle strength and motor function in adolescents and adults with spinal muscular atrophy
Wijngaarde, C. A., Stam, M., Otto, L. A. M., Bartels, B., Asselman, F., van Eijk, R. P. A., van den Berg, L. H., Goedee, H. S., Wadman, R. I., & van der Pol, W. L. (2020) · Neurology · doi:10.1212/wnl.0000000000010540 · Cited by 102
“, the HFMSE and MFM, have been the primary tools for natural history studies and clinical trials.(5,6,9,40,41) These studies have been performed primarily in younger children with SMA, usually with follow-up periods of ≤3 years.”
MethodTRIM11 protects against tauopathies and is down-regulated in Alzheimer’s disease
Zhang, Z.-Y., Harischandra, D. S., Wang, R., Ghaisas, S., Zhao, J. Y., McMonagle, T. P., Zhu, G., Lacuarta, K. D., Song, J., Trojanowski, J. Q., et al. (2023) · Science · doi:10.1126/science.add6696 · Cited by 95
“AAVs can transduce the nondividing neurons and permit permanent expression of the therapeutic gene after a single administration (73, 74), with positive clinical outcomes (75).”
Gene therapy for CNS disorders: modalities, delivery and translational challenges
Gao, J., Gunasekar, S., Xia, Z. J., Shalin, K., Jiang, C., Chen, H., Lee, D., Lee, S., Pisal, N. D., Luo, J. N., et al. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-024-00829-7 · Cited by 102
In Vivo Ryr 2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia
Pan, X., Philippen, L., Lahiri, S. K., Lee, C., Park, S. H., Word, T. A., Li, N., Jarrett, K. E., Gupta, R., Reynolds, J. O., et al. (2018) · Circulation Research · doi:10.1161/circresaha.118.313369 · Cited by 95
Lyon, A. R., Babalis, D. S., Morley-Smith, A. C., Hedger, M., Barrientos, A. S., Földes, G., Couch, L. S., Chowdhury, R. A., Tzortzis, K. N., Peters, N. S., et al. (2020) · Gene Therapy · doi:10.1038/s41434-020-0171-7 · Cited by 110
Butchbach, M. E. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157896 · Cited by 117
Ogbonmide, T., Rathore, R., Rangrej, S. B., Hutchinson, S., Lewis, M., Ojilere, S., Carvalho, V., & Kelly, I. (2023) · Cureus · doi:10.7759/cureus.36197 · Cited by 165
“After the Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy study [15], all 15 patients survived treatment and improved over time.”
MethodNusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function
Pane, M., Palermo, C., Messina, S., Sansone, V., Bruno, C., Catteruccia, M., Sframeli, M., Albamonte, E., Pedemonte, M., D’Amico, A., et al. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2018.05.010 · Cited by 100
Dabbous, O., Maru, B., Jansen, J. P., Lorenzi, M., Cloutier, M., Guérin, A., Pivneva, I., Wu, E. Q., Arjunji, R., Feltner, D., et al. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00923-8 · Cited by 93
Self-citationAdvances in spinal muscular atrophy therapeutics
Parente, V., & Corti, S. P. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285618754501 · Cited by 106
Garrison, L. P., Jackson, T., Paul, D. R., & Kenston, M. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.18378 · Cited by 116
Delling, J. P., & Boeckers, T. M. (2021) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-021-09397-8 · Cited by 109
“Especially therapies developed for spinal muscular atrophy type 1 [247, 248], or the manipulation of gene products rather than the DNA itself [249, 250] like targeting haploinsufficiencies by CRISPR-mediated gene activation via promotors or enhancers [249], might serve as a proof of principle for other genetic disorde…”
BackgroundRozas, P., Kessi‐Pérez, E. I., & Martínez, C. (2022) · Biological Research · doi:10.1186/s40659-022-00399-x · Cited by 112
“Luxturna and Zolgensma are adeno-associated virus (AAV) gene therapies for RPE65 mutation-associated retinal dystrophy and spinal muscular atrophy (SMA), replacing the dysfunctional alleles of the RPE65 or SMN1 gene, respectively, with their functional copies [74, 75].”
BackgroundChemical modification of the adeno-associated virus capsid to improve gene delivery
Mével, M., Bouzelha, M., Leray, A., Pacouret, S., Guilbaud, M., Penaud-Budloo, M., Alvarez-Dorta, D., Dubreil, L., Gouin, S. G., Combal, J. P., et al. (2020) · Chemical Science · doi:10.1039/c9sc04189c · Cited by 92
AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy
Pattali, R. K., Mou, Y., & Li, X.-J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0085-4 · Cited by 107
Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders
Hill, S. F., & Meisler, M. H. (2021) · Developmental Neuroscience · doi:10.1159/000517686 · Cited by 90
Gene therapy clinical trials worldwide to 2023—an update
Ginn, S. L., Mandwie, M., Alexander, I. E., Edelstein, M. L., & Abedi, M. R. (2024) · The Journal of Gene Medicine · doi:10.1002/jgm.3721 · Cited by 112
Ruhno, C., McGovern, V. L., Avenarius, M. R., Snyder, P. J., Prior, T. W., Nery, F. C., Muhtaseb, A. W., Roggenbuck, J., Kissel, J. T., Sansone, V., et al. (2019) · Human Genetics · doi:10.1007/s00439-019-01983-0 · Cited by 97
Self-citationUnderstanding AAV vector immunogenicity: from particle to patient
Dhungel, B. P., Winburn, I. C., Pereira, C. D. F., Huang, K., Chhabra, A., & Rasko, J. E. J. (2024) · Theranostics · doi:10.7150/thno.89380 · Cited by 101
“For example, patients with pre-existing anti-AAV9 NAbs above a threshold were excluded from a phase 1 spinal muscular atrophy clinical trial [68] as were patients with anti-AAV5 NAbs from a phase 3 clinical trial for hemophilia A [69].”
BackgroundKoh, H. Y., Zheng, Y., Yang, M., Arora, R., Webb, G. I., Pan, S., Li, L., & Church, G. M. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00349-8 · Cited by 147
“Experimental validation of the top 30 mutants revealed up to a 37-fold increase in binding affinity against escape variants BQ.1.1 and XBB.1.5, demonstrating the advantage of integrating AI with structural insights to optimize antibodies for evolving viral epitopes.”
InfluentialT Cell-Mediated Immune Responses to AAV and AAV Vectors
Ertl, H. C. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666666 · Cited by 88
Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain
Sumner, C. J., & Crawford, T. O. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121658 · Cited by 88
Clinical development on the frontier: gene therapy for duchenne muscular dystrophy
Asher, D. R., Thapa, K., Dharia, S. D., Khan, N., Potter, R. A., Rodino‐Klapac, L. R., & Mendell, J. R. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1725469 · Cited by 100
Self-citationAAV ablates neurogenesis in the adult murine hippocampus
Johnston, S., Parylak, S. L., Kim, S., Mac, N., Lim, C., Gallina, I., Bloyd, C., Newberry, A., Saavedra, C. D., Novak, O., et al. (2021) · eLife · doi:10.7554/elife.59291 · Cited by 87
“Careful consideration of viral titer, delivery method, and viral engineering should be exercised to mitigate side effects where viral therapy may substantially alleviate morbidity or extend life (Mendell et al., 2017).”
BackgroundCombating deleterious phase transitions in neurodegenerative disease
Darling, A. L., & Shorter, J. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.118984 · Cited by 85
Jensen, T. L., Gøtzsche, C. R., & Woldbye, D. P. D. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.695937 · Cited by 102
Zeviani, M., & Carelli, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010210 · Cited by 95
Govoni, A., Gagliardi, D., Comi, G. P., & Corti, S. P. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0831-9 · Cited by 98
Wang, L., Yang, Y., Breton, C. A., White, J., Zhang, J., Che, Y., Saveliev, A., McMenamin, D., He, Z., Latshaw, C., et al. (2019) · Blood · doi:10.1182/blood.2019000790 · Cited by 93
Nicolau, S., Waldrop, M. A., Connolly, A. M., & Mendell, J. R. (2021) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2021.100878 · Cited by 104
Self-citationGonzalez, T. J., Simon, K. E., Blondel, L. O., Fanous, M. M., Roger, A. L., Maysonet, M. S., Devlin, G. W., Smith, T. J., Oh, D. K., Havlik, L. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33745-4 · Cited by 85
Efficient Gene Transfer to the Central Nervous System by Single-Stranded Anc80L65
Hudry, E., Andres-Mateos, E., Lerner, E. P., Volak, A., Cohen, O., Hyman, B. T., Maguire, C. A., & Vandenberghe, L. H. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.07.006 · Cited by 84
“delivery of AAV in multiple animal models, and a first clinical trial has been approved by the FDA to use systemic delivery of AAV9 for the treatment of infantile spinal muscular atrophy type 1.(22) Considering that Anc80L65 is the predicted synthetic ancestor of AAV serotypes 1, 2, 8, and 9, we hypothesized that it m…”
BackgroundMethodEvading and overcoming AAV neutralization in gene therapy
Earley, J., Piletska, E. V., Ronzitti, G., & Piletsky, S. A. (2022) · Trends in biotechnology · doi:10.1016/j.tibtech.2022.11.006 · Cited by 93
Zabaleta, N., Dai, W., Bhatt, U., Hérate, C., Maisonnasse, P., Chichester, J. A., Sanmiguel, J. C., Estelien, R., Michalson, K. T., Diop, C., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.08.002 · Cited by 91
“Its applications to data are primarily in the field of therapeutic gene transfer and have now led to 3 approved AAV-based gene therapy products (Bennett et al., 2016; Mendell et al., 2017; Stroes et al., 2008).”
InfluentialSafe and effective in vivo delivery of DNA and RNA using proteolipid vehicles
Brown, D. W., Wee, P., Bhandari, P., Bukhari, A. B., Grin, L., Vega, H., Hejazi, M., Sosnowski, D. L., Ablack, J., Clancy, E. K., et al. (2024) · Cell · doi:10.1016/j.cell.2024.07.023 · Cited by 88
Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort
Perocheau, D. P., Cunningham, S. C., Lee, J., Antinao Diaz, J., Waddington, S. N., Gilmour, K., Eaglestone, S., Lisowski, L., Thrasher, A. J., Alexander, I. E., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.098 · Cited by 81
Prasad, S., Dimmock, D. P., Greenberg, B., Walia, J. S., Sadhu, C., Tavakkoli, F., & Lipshutz, G. S. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.138 · Cited by 81
Gene Therapy for Parkinson’s Disease Associated with GBA1 Mutations
Abeliovich, A., Hefti, F. F., & Sevigny, J. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212739 · Cited by 102
Therapeutic strategies for glucose transporter 1 deficiency syndrome
Tang, M., Park, S. H., Vivo, D. C. D., & Monani, U. R. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50881 · Cited by 83
Roy, B., Lee, E. J., Li, T., & Rampersaud, M. (2022) · Genes · doi:10.3390/genes13030425 · Cited by 89
Servais, L., Day, J., Vivo, D. C. D., Kirschner, J., Mercuri, E. M., Muntoni, F., Proud, C. M., Shieh, P. B., Tizzano, E. F., Quijano-Roy, S., et al. (2024) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-230122 · Cited by 92
“These findings further validate substantial improvement and outcome gains versus the natural history of SMA [9, 15–17, 27, 29, 31–34, 38].”
BackgroundMethodResultInfluentialChallenges and opportunities in spinal muscular atrophy therapeutics
Yeo, C. J. J., Tizzano, E. F., & Darras, B. T. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00419-2 · Cited by 100
Bonnycastle, K., Davenport, E. C., & Cousin, M. A. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15035 · Cited by 83
Combination molecular therapies for type 1 spinal muscular atrophy
Harada, Y., Rao, V. K., Arya, K., Kuntz, N. L., DiDonato, C. J., Napchan‐Pomerantz, G., Agarwal, A., Stefans, V., Katsuno, M., & Veerapandiyan, A. (2020) · Muscle & Nerve · doi:10.1002/mus.27034 · Cited by 90
“It is a one-time intravenous SMN gene replacement therapy using a non-replicating, self-complementary, adeno-associated virus (AAV) serotype 9 carrying SMN complementary DNA encoding the SMN protein.(1,8,9) Data on experience of combination molecular therapies for SMA is lacking.”
BackgroundMethodChhabra, A., Bashirians, G., Petropoulos, C. J., Wrin, T., Paliwal, Y., Henstock, P. V., Somanathan, S., Pereira, C. D. F., Winburn, I. C., & Rasko, J. E. J. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101273 · Cited by 92
Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques
Borel, F., Gernoux, G., Sun, H., Stock, R., Blackwood, M., Brown, R. H., & Mueller, C. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aau6414 · Cited by 78
Musculoskeletal tissue engineering: Regional gene therapy for bone repair
Collon, K. W., Gallo, M. C., & Lieberman, J. R. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120901 · Cited by 90
Zhu, X., Xu, J., Ling, G., & Zhang, P. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00386h · Cited by 79
Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy
Blair, H. A. (2022) · CNS Drugs · doi:10.1007/s40263-022-00941-1 · Cited by 97
Longitudinal natural history of type I spinal muscular atrophy: a critical review
Mercuri, E. M., Lucibello, S., Perulli, M., Coratti, G., Sanctis, R. D., Pera, M. C., Pane, M., Montes, J., Vivo, D. C. D., Darras, B. T., et al. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01356-1 · Cited by 80
“Our cumulative results confirm that, even when a larger cohort of type I infants is included, there is never a consistent functional improvement in type I SMA infants that, in contrast, is frequently observed in treated patients in different published or ongoing clinical studies [10, 19, 20] or in recent real world da…”
ResultChowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 82
Extracellular vesicles set the stage for brain plasticity and recovery by multimodal signalling
Hermann, D. M., Peruzzotti-Jametti, L., Giebel, B., & Pluchino, S. (2024) · Brain · doi:10.1093/brain/awad332 · Cited by 77
“186,187 To enhance their biological properties, EVs may genetically be loaded with defined genes or proteins (Fig.”
BackgroundOptimising mechanical ventilation through model-based methods and automation
Morton, S. E., Knopp, J. L., Chase, J. G., Docherty, P. D., Howe, S. L., Möller, K., Shaw, G. M., & Tawhai, M. H. (2019) · Annual Reviews in Control · doi:10.1016/j.arcontrol.2019.05.001 · Cited by 77
How to discuss gene therapy for haemophilia? A patient and physician perspective
Miesbach, W., O’Mahony, B., Key, N. S., & Makris, M. (2019) · Haemophilia · doi:10.1111/hae.13769 · Cited by 113
Boemer, F., Caberg, J., Beckers, P., Dideberg, V., di Fiore, S., Bours, V., Marie, S., Dewulf, J. P., Marcélis, L., Deconinck, N., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99496-2 · Cited by 83
Moving towards clinical trials for mitochondrial diseases
Pitceathly, R. D. S., Keshavan, N., Rahman, J., & Rahman, S. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12281 · Cited by 82
Current and potential new treatment strategies for creatine deficiency syndromes
Fernandes-Pires, G., & Braissant, O. (2022) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.12.005 · Cited by 72
TDP-43 pathology: From noxious assembly to therapeutic removal
Keating, S. S., Gil, R. S., Swanson, M. E. V., Scotter, E. L., & Walker, A. K. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102229 · Cited by 88
Tran, N. T., Lecomte, E., Saleun, S., Namkung, S., Robin, C., Weber, K., Devine, E., Blouin, V., Adjali, O., Ayuso, E., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.050 · Cited by 74
Kay, D. M., Stevens, C. F., Parker, A., Saavedra‐Matiz, C. A., Sack, V., Chung, W. K., Chiriboga, C. A., Engelstad, K., Laureta, E. C., Farooq, O., et al. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-0824-3 · Cited by 87
Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy
D’Silva, A., Holland, S., Kariyawasam, D. S. T., Herbert, K., Barclay, P. G., Cairns, A. G., MacLennan, S. C., Ryan, M. M., Sampaio, H. A., Smith, N. J. C., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51519 · Cited by 76
Colella, P., Sellier, P., Costa Verdera, H., Puzzo, F., van Wittenberghe, L., Guerchet, N., Daniele, N., Gjata, B., Marmier, S., Charles, S., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.002 · Cited by 74
Antisense oligonucleotides and other genetic therapies made simple
Rossor, A. M., Reilly, M. M., & Sleigh, J. N. (2018) · Practical Neurology · doi:10.1136/practneurol-2017-001764 · Cited by 77
Suzuki‐Hatano, S., Saha, M., Rizzo, S. A., Witko, R. L., Gosiker, B. J., Ramanathan, M., Soustek, M. S., Jones, M. D., Kang, P. B., Byrne, B. J., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.020 · Cited by 75
“As a multitude of AAV-mediated gene delivery strategies are currently being evaluated for clinical efficacy in humans to treat a range of genetically inherited disorders (spinal muscular atrophy, hemophilia), a strong precedent exists for our strategy to be successfully implemented as a valid therapy.(39,44) Thus, our…”
Gautier, B., Hajjar, H., Soares, S., Berthelot, J., Deck, M., Abbou, S., Campbell, G. R., Ceprián, M., Gonzalez, S., Fovet, C.-M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22593-3 · Cited by 79
Sevigny, J., Uspenskaya, O., Heckman, L. D., Wong, L. C., Hatch, D. A., Tewari, A., Vandenberghe, R. R., Irwin, D. J., Saracino, D., Ber, I. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02973-0 · Cited by 90
A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders
Vrellaku, B., Hassan, I. S., Howitt, R., Webster, C. P., Harriss, E., McBlane, F., Betts, C., Schettini, J. L., Lion, M., Mindur, J. E., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.016 · Cited by 84
Müller‐Felber, W., Vill, K., Schwartz, O., Gläser, D., Nennstiel, U., Wirth, B., Burggraf, S., Röschinger, W., Becker, M., Durner, J., et al. (2020) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-200475 · Cited by 73
“Moreover, with new therapies such as gene therapy coming along, a therapeutic intervention is only possible in early childhood [53].”
BackgroundAAV Capsid-Promoter Interactions Determine CNS Cell-Selective Gene Expression In Vivo
Powell, S. K., Samulski, R. J., & McCown, T. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.03.007 · Cited by 71
Hensel, N., Kubinski, S., & Claus, P. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00045 · Cited by 79
“Similarly, patients treated early with Onasemnogene Abeparvovec/Zolgensma R © performed better compared to patients with delayed intervention (51).”
BackgroundHacker, U. T., Bentler, M., Kaniowska, D., Morgan, M., & Büning, H. (2020) · Cancers · doi:10.3390/cancers12071889 · Cited by 71
“AAV9 was chosen due to the ability to cross the Blood–Brain-Barrier (BBB) when applied intravenously followed by motor neuron transduction [30,31].”
BackgroundMethodSkeletal Muscle in ALS: An Unappreciated Therapeutic Opportunity?
Scaricamazza, S., Salvatori, I., Ferri, A., & Valle, C. (2021) · Cells · doi:10.3390/cells10030525 · Cited by 76
“The treatment involved the injection of antisense oligonucleotides (ASOs) [25,26] or viral vectors [27] in restoring SMN1 protein levels [28].”
BackgroundAdeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
Jablonka, S., Hennlein, L., & Sendtner, M. (2022) · Neurological Research and Practice · doi:10.1186/s42466-021-00162-9 · Cited by 86
Atrial-Specific Gene Delivery Using an Adeno-Associated Viral Vector
Ni, L., Scott, L., Campbell, H. M., Pan, X., Alsina, K. M., Reynolds, J. O., Philippen, L. E., Hulsurkar, M. M., Lagor, W. R., Li, N., et al. (2019) · Circulation Research · doi:10.1161/circresaha.118.313811 · Cited by 70
AAV9 Edits Muscle Stem Cells in Normal and Dystrophic Adult Mice
Nance, M. E., Shi, R., Hakim, C. H., Wasala, N. B., Yue, Y., Pan, X., Zhang, T., Robinson, C. A., Duan, S. X., Yao, G., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.06.012 · Cited by 79
“Recent success of systemic AAV9 therapy in spinal muscular atrophy type 1 patients has further raised the hope of clinical translation.(21) In fact, several human trials have been initiated in DMD patients to test systemic AAV9 microdystrophin gene replacement therapy.”
BackgroundMin, Y.-L., Chemello, F., Li, H. Z., Rodríguez-Caycedo, C., Sanchez‐Ortiz, E., Mireault, A. A., McAnally, J., Shelton, J. M., Zhang, Y., Bassel‐Duby, R., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.024 · Cited by 80
Dangouloff, T., Burghes, A. H. M., Tizzano, E. F., Servais, L., Bertini, E., Boemer, F., Hiligsmann, M., Mueller‐Felber, W., Tiziano, F. D., Young, P. J., et al. (2019) · Neuromuscular Disorders · doi:10.1016/j.nmd.2019.11.002 · Cited by 82
Self-citationSrivastava, A. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.014 · Cited by 71
Ding, W. Y., Kuzmuk, V., Hunter, S., Lay, A. C., Hayes, B., Beesley, M., Rollason, R., Hurcombe, J., Barrington, F., Masson, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abc8226 · Cited by 78
Metadata
- Authors
- Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., Kissel, J. T., Nagendran, S., L’Italien, J., Sproule, D. M., Wells, C., Cardenas, J. A., Heitzer, M. D., Kaspar, A., Corcoran, S., Braun, L., Likhite, S., Miranda, C., Meyer, K., Foust, K. D., Burghes, A. H. M., & Kaspar, B. K.
- Affiliations
- Abigail Wexner Research Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-02
- Volume
- 377
- Issue
- 18
- Pages
- 1713-1722
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2765253110
- Cited by
- 2,381
- References
- 26
- Citations by year
- 2026: 205 · 2025: 232 · 2024: 292 · 2023: 270 · 2022: 289 · 2021: 347 · 2020: 298 · 2019: 246 · 2018: 172 · 2017: 16
- FWCI
- 115.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Nationwide Children's Hospital
- AveXis
- Research Institute, Nationwide Children's Hospital
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- spinal muscular atrophy type 1, gene replacement therapy, adeno-associated virus vectors, SMN1, motor function, motor milestones, survival, CHOP INTEND, aminotransferase elevation, prednisolone, treatment efficacy and safety
- MeSH terms
- Dependovirus, Female, Genetic Vectors, Humans, Infant, Infant, Newborn, Infusions, Intravenous, Liver Diseases, Male, Motor Skills, Respiration, Artificial, Spinal Muscular Atrophies of Childhood, Genetic Therapy, Cohort Studies, Nutritional Support, Disease-Free Survival, Survival of Motor Neuron 1 Protein, Historically Controlled Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.